CureledgerCureledger
ReferencesBlog
Join

Blog

The case for patient-controlled rare disease data across science, policy, and the lived experience.

Featured

Patient Experience

What we still have to do

The structural friction of rare disease daily life.

Read →

This week

Data Sovereignty

Unpaid data farmers

The data work we have been doing for free, finally compensated.

Read →
Vision

The flywheel

Cohort proof licensed. Contribution measured. Deposit lands.

Read →
Science & Data

Cohort proofs

Privacy from cryptography. Validation without exposure.

Read →

Search articles

Browse by tag

Clear ×
Patient ExperienceData SovereigntyVisionScience & DataRegulatoryUltra-rareAccelerating innovationEhlers-DanlosNewborn screeningCompanyHistory
Read all10 of 116 · Tag: Ultra-rare
↓
  1. May 7, 2026Ethan Perlstein and the other n-of-1Ultra-rare
  2. May 7, 2026Adrian Krainer and the splicing mechanism that became SpinrazaUltra-rare
  3. May 7, 2026Wendy Chung and the natural-history-first modelUltra-rare
  4. May 7, 2026Steven Gray and the AAV9 platform for rare brain diseaseUltra-rare
  5. May 7, 2026Stanley Crooke and the n-of-many foundationUltra-rare
  6. May 7, 2026Timothy Yu and the lab that built the first individualized drugUltra-rare
  7. May 7, 2026AAV gene therapy at single-patient scaleUltra-rare
  8. May 7, 2026How splice-switching ASOs workUltra-rare
  9. May 7, 2026What an n-of-1 trial actually isUltra-rare
  10. Apr 28, 2026The network, and why it existsUltra-rare
About·For investors·Privacy··

© 2026 Cureledger Inc. · Raleigh, NC USA